Cipla, Glenmark and Emcure significantly outperformed the market, with yoy growth of 19.9%, 38.8% and 24.9%, respectively.

India Ratings and Research (Ind-Ra) opines the 14.1% yoy growth in India’s pharmaceutical market (IPM) during June 2021 was led by a normalisation of demand post high growth months of April 2021 (51.5% growth) and May 2021 (47.8%).

Leave a Reply

Your email address will not be published. Required fields are marked *